C50
Conditions
Interventions
Group 1: Women diagnosed with BC between the ages of 18 and 39 years treated in University Hospital for Gynecology, Pius-Hospital Oldenburg, between January 2010 and December 2019.
Sponsors
Pius-Hospital Oldenburg, Universitätsklinik für Gynäkologie
Eligibility
Sex/Gender
Female
Age
18 Years to 40 Years
Inclusion criteria
Inclusion criteria: 1. Women between 18 and 39 years, 2. Cases with confirmed diagnosis of BC 3. Cases diagnosed between January 1, 2010 and December 31, 2019 4. Cases treated at Pius Hospital
Exclusion criteria
Exclusion criteria: 1. Age: 39 years 2. Unconfirmed BC diagnosis 3. Previous history of any invasive cancer 4. A lack of information on clinical and pathological tumor characteristics 5. Patients who at time of treatment initiation have had an explicit non-consent for data analysis 6. All cases of breast cancer diagnosed before January 1, 2010 and after December 31, 2019
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To determine the oncological outcomes (RR, FDP, MR, RFS, OS) according to tumor biology of patients diagnosed with BC before the age of 40 years who received treatment at the University Hospital for Gynecology at Pius Hospital of Oldenburg between January 2010 and December 2019. | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. To describe the patients´ clinical characteristics at diagnosis (age, BMI, parity, Blood analysis, etc.) 2. To describe the tumor stage and tumor biological characteristics of the study population (stadium, histopathology, grade, receptor status, etc). 3. To identify the type of treatment received according to tumor biology and disease stage. 4. To identify the therapy compliance at initial management. 5. To estimate the mean size of residual tumor after neoadjuvant chemotherapy. 6. To estimate the recurrence rate (RR) according to stage and type of treatment. 7. To estimate the free of disease period (FDP) according to stage and type of treatment. 8. To estimate the recurrence-free survival rate (RFS) according to stage and type of treatment. 9. To calculate the mortality rate (MR) according to stage and type of treatment. 10. To estimate the overall survival (OS) rate according to stage and type of treatment. 11. To describe the reproductive outcomes (fertility, course of pregnancy, complications related to pregnancy/breast-feeding) of women who got pregnant after treatment. 12. To estimate the complications and adverse events frequency according to provided treatment. | — |
Countries
Germany
Contacts
Public ContactRudy Leon De Wilde
Pius-Hospital Oldenburg, Universitätsklinik für Gynäkologie
Outcome results
None listed